Article
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
30 Jul 2015
Abstract excerpt
More potent targeting of the androgen receptor (AR) in advanced prostate cancer is driving an increased incidence of neuroendocrine prostate cancer (NEPC), an aggressive and treatment-resistant AR-negative variant. Its molecular pathogenesis remains poorly understood but appears to require TP53 and RB1 aberration. We modeled the development of NEPC from conventional prostatic adenocarcinoma using a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
